指南与共识医院感染防控细菌感染、耐药与抗菌药物

ESCMID 免疫功能受损宿主感染研究组(ESGICH)关于靶向和生物制剂安全性的共识文件:感染病学视角(可溶性免疫效应分子[II]:靶向白介素、免疫球蛋白和补体因子的药物)

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).
指南 / 共识 · Clin Microbiol Infect · 2018-02-12

本共识从感染病学角度综述靶向白介素、免疫球蛋白和补体因子药物的安全性。IL-1或IL-5靶向药物感染风险中等且无特定预防策略推荐;IL-6/IL-6受体靶向药物风险增加与抗TNF-α药物相似;IL-12/23靶向药物似乎不构成有意义的感染风险,但可考虑筛查潜伏结核,HBsAg阳性患者应给予抗病毒预防;IL-17靶向药物可能导致轻至中度皮肤黏膜念珠菌病;使用IgE靶向药物前应考虑筛查粪类圆线虫等土源性蠕虫;C5靶向药物显著增加荚膜细菌感染风险,尤其是奈瑟菌属,必须在开始治疗前2-4周接种脑膜炎球菌疫苗并给予化学预防。

要点

  • IL-1或IL-5靶向药物感染风险中等,无特定预防策略推荐。
  • C5靶向药物显著增加荚膜细菌感染风险,尤其是奈瑟菌属,必须接种疫苗和化学预防。
  • IL-17靶向药物可能导致轻至中度皮肤黏膜念珠菌病。

核心结论

  • IL-1或IL-5靶向药物感染风险中等且无特定预防策略推荐;IL-6/IL-6受体靶向药物风险增加与抗TNF-α药物相似;IL-12/23靶向药物似乎不构成有意义的感染风险;IL-17靶向药物可能导致轻至中度皮肤黏膜念珠菌病;使用IgE靶向药物前应考虑筛查粪类圆线虫等土源性蠕虫;C5靶向药物显著增加荚膜细菌感染风险,尤其是奈瑟菌属,必须接种脑膜炎球菌疫苗和化学预防;应特别鼓励采取预防策略以最小化与依库珠单抗相关的奈瑟菌感染。

研究设计与样本

  • ESCMID免疫功能受损宿主感染研究组(ESGICH)共识文件,基于计算机MEDLINE检索,检索词为与每种药物或治疗类别相关的MeSH术语。

主要发现

  • 接受IL-1靶向药物(阿那白滞素、卡那奴单抗或利纳西普)或IL-5靶向药物(美泊利珠单抗)的患者感染风险中等,无特定预防策略推荐。
  • 使用IL-6/IL-6受体靶向药物(托珠单抗和西妥昔单抗)与观察到的抗肿瘤坏死因子-α药物相似的风险增加相关。
  • IL-12/23靶向药物(乌司奴单抗)似乎不构成有意义的感染风险,但可考虑筛查潜伏结核感染,乙型肝炎表面抗原阳性患者应给予抗病毒预防。
  • IL-17靶向药物(苏金单抗、布罗达鲁单抗和伊克珠单抗)治疗可能导致轻至中度皮肤黏膜念珠菌病。
  • 对于来自粪类圆线虫和其他土源性蠕虫流行地区的患者,接受IgE靶向药物(奥马珠单抗)前应考虑筛查粪类圆线虫和其他土源性蠕虫。

关键数值与推荐

  • 接受IL-1靶向药物(阿那白滞素、卡那奴单抗或利纳西普)或IL-5靶向药物(美泊利珠单抗)的患者感染风险中等,无特定预防策略推荐。
  • 使用IL-6/IL-6受体靶向药物(托珠单抗和西妥昔单抗)与观察到的抗肿瘤坏死因子-α药物相似的风险增加相关。
  • IL-12/23靶向药物(乌司奴单抗)似乎不构成有意义的感染风险,但可考虑筛查潜伏结核感染,乙型肝炎表面抗原阳性患者应给予抗病毒预防。
  • 使用IL-17靶向药物(苏金单抗、布罗达鲁单抗和伊克珠单抗)可能导致轻至中度皮肤黏膜念珠菌病。
  • 对于来自粪类圆线虫和其他土源性蠕虫流行地区的患者,接受IgE靶向药物(奥马珠单抗)前应考虑筛查粪类圆线虫和其他土源性蠕虫。

临床怎么用

  • C5靶向药物(依库珠单抗)与荚膜细菌(尤其是奈瑟菌属)感染风险显著增加相关;必须在开始依库珠单抗前2-4周接种脑膜炎球菌疫苗并给予化学预防。
  • 有高危行为者及其伴侣应筛查淋球菌感染。
  • 应特别鼓励采取预防策略以最小化与依库珠单抗相关的奈瑟菌感染。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies. AIMS: To review, from an Infectious Diseases perspective, the safety profile of agents targeting interleukins, immunoglobulins and complement factors and to suggest preventive recommendations. SOURCES: Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic family. CONTENT: Patients receiving interleukin-1 (IL-1) -targeted (anakinra, canakinumab or rilonacept) or IL-5-targeted (mepolizumab) agents have a moderate risk of infection and no specific prevention strategies are recommended. The use of IL-6/IL-6 receptor-targeted agents (tocilizumab and siltuximab) is associated with a risk increase similar to that observed with anti-tumour necrosis factor-α agents. IL-12/23-targeted agents (ustekinumab) do not seem to pose a meaningful risk of infection, although screening for latent tuberculosis infection may be considered and antiviral prophylaxis should be given to hepatitis B surface antigen-positive patients. Therapy with IL-17-targeted agents (secukinumab, brodalumab and ixekizumab) may result in the development of mild-to-moderate mucocutaneous candidiasis. Pre-treatment screening for Strongyloides stercoralis and other geohelminths should be considered in patients who come from areas where these are endemic who are receiving IgE-targeted agents (omalizumab). C5-targeted agents (eculizumab) are associated with a markedly increased risk of infection due to encapsulated bacteria, particularly Neisseria spp. Meningococcal vaccination and chemoprophylaxis must be administered 2-4 weeks before initiating eculizumab. Patients with high-risk behaviours and their partners should also be screened for gonococcal infection. IMPLICATIONS: Preventive strategies are particularly encouraged to minimize the occurrence of neisserial infection associated with eculizumab.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Winthrop KL, Mariette X, Silva JT, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect. 2018. PMID: 29447987. doi:10.1016/j.cmi.2018.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。